ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstracts tagged "IL-6"

  • Abstract Number: 982 • 2018 ACR/ARHP Annual Meeting

    In the Presence of IL-18, IL-10 but Not IL-6 Induces IFN-γ Production and the Surface Expression of TRAIL on NK Cells

    Kojiro Sato, Yoshimi Aizaki, Hiroaki Yazawa and Toshihide Mimura, Department of Rheumatology and Applied Immunology, Faculty of Medicine, Saitama Medical University, Saitama, Japan

    Background/Purpose: Adult-onset Still’s disease (AOSD) is a systemic inflammatory disease, the cause of which is largely unknown. AOSD has been recently classified as one of…
  • Abstract Number: 2900 • 2018 ACR/ARHP Annual Meeting

    Impaired TCR Signaling Paves the Way for Cytokine Hyper-Responsiveness in Arthritogenic T Cells

    Judith Ashouri1, Lih-Yun Hsu1, Dmitry Rychkov2, Marina Sirota2, Lisa Lattanza3, Eric Hansen3, Julie Zikherman1 and Arthur Weiss1, 1Rosalind Russell and Ephraim P. Engleman Rheumatology Research Center, Department of Medicine, Division of Rheumatology, University of California, San Francisco, San Francisco, CA, 2Pediatrics, Institute for Computational Health Sciences, University of California, San Francisco, San Francisco, CA, 3Orthopedic Surgery, University of California, San Francisco, San Francisco, CA

    Background/Purpose: The inability to identify relevant arthritogenic CD4 T cells in patients and in murine disease models has limited our understanding of disease initiating events…
  • Abstract Number: 992 • 2018 ACR/ARHP Annual Meeting

    Epigallocatechin-3-Gallate (EGCG) Suppresses Systemic Inflammation By Inhibiting IL-6-Induced STAT3 Activation in Cultured Hepatocytes and in Liver Tissue of Adjuvant-Induced Arthritis (AIA) Rats

    Anil K. Singh1, Sabrina Fechtner2, Dorothy Wang2, Mukesh Chourasia3 and Salahuddin Ahmed2,4, 1Washington State University, College of Pharmacy, Spokane, WA, 2Department of Pharmaceutical Sciences, Washington State University, College of Pharmacy, Spokane, WA, 3Department of Pharmacoinformatics,, National lnstitute of Pharmaceutical Education and Research, Hajipur,, India, 4Division of Rheumatology, University of Washington, Division of Rheumatology, School of Medicine, Seattle, WA

    Background/Purpose: In rheumatoid arthritis (RA), the pro-inflammatory cytokine interleukin-6 (IL-6) induces systemic inflammation by activating hepatocytes through IL-6 receptor (IL-6R)- mediated JAK/STAT3 signaling pathway. The…
  • Abstract Number: 1052 • 2018 ACR/ARHP Annual Meeting

    Detection of Precursors of RANK- Osteoclast-like Cells (Olcs) in Peripheral Blood and Olcs in Bone Tissue from Rheumatoid Arthritis Patients

    Kazuhiro Yokota1, Shinya Tanaka2, Miyoko Sekikawa2, Yoshimi Aizaki1, Kojiro Sato1, Hiromi Oda2 and Toshihide Mimura1, 1Department of Rheumatology and Applied Immunology, Faculty of Medicine, Saitama Medical University, Saitama, Japan, 2Department of Orthopaedic Surgery, Saitama Medical University, Saitama, Japan

    Background/Purpose: Proinflammatory cytokines play an important role in bone destruction in rheumatoid arthritis (RA), as inferred by the efficacy of biologics. Previously, we reported that…
  • Abstract Number: 1053 • 2018 ACR/ARHP Annual Meeting

    Synovial Inflammation Identifies Patients Clusters in Osteoarthritis

    Hannah Labinsky1, Paul Panipinto1, Kaytlyn Ly2, Deric Khuat2, Bhanupriya Madarampalli3, Vineet Mahajan1, Jonathan Clabeaux4, Kevin MacDonald4, Peter Verdin4, Jane H. Buckner2 and Erika H. Noss3, 1Medicine, Division of Rheumatology, University of Washington, Seattle, WA, 2Benaroya Research Institute at Virginia Mason, Seattle, WA, 3Rheumatology, University of Washington, Seattle, WA, 4Orthopedics, Virginia Mason Hospital, Seattle, WA

    Background/Purpose: Synovial membrane inflammation is common in osteoarthritis (OA). Inflammation may be present at all disease stages, increases the risk of cartilage injury, and is…
  • Abstract Number: 1511 • 2018 ACR/ARHP Annual Meeting

    The Relationship between Lipid Profile Changes and Inflammation across the Phase 3 Sarilumab Rheumatoid Arthritis (RA) Developmental Program

    Christina Charles-Schoeman1, Gregory St. John2, Henry Leher2, Toshio Kimura2, Hubert van Hoogstraten3, Michael T. Nurmohamed4, Miguel Angel González-Gay5 and Edward C. Keystone6, 1Rheumatology, UCLA David Geffen School of Medicine, Los Angeles, CA, 2Regeneron Pharmaceuticals, Inc., Tarrytown, NY, 3Sanofi Genzyme, Bridgewater, NJ, 4VU University Medical Center, Amsterdam, Netherlands, 5University Hospital Marques de Valdecilla, Santander, Spain, 6University of Toronto and Mount Sinai Hospital, Toronto, ON, Canada

    Background/Purpose: Sarilumab showed superiority to placebo and adalimumab in Phase 3 trials. Serum lipids may be reduced in the setting of chronic inflammation associated with…
  • Abstract Number: 1521 • 2018 ACR/ARHP Annual Meeting

    Anti-IL-6 Therapy Modulates Leptin in Patients with Rheumatoid Arthritis

    Sara Remuzgo-Martínez1, Fernanda Genre1, Verónica Pulito-Cueto1, Verónica Mijares1, Leticia Lera-Gómez1, Jaime Calvo-Alén2, Ricardo Blanco1, Oreste Gualillo3, Javier Llorca4, Santos Castañeda5, Raquel Lopez-Mejías1 and Miguel Angel González-Gay1,6,7, 1Epidemiology, Genetics and Atherosclerosis Research Group on Systemic Inflammatory Diseases, IDIVAL, Santander, Spain, Santander, Spain, 2Rheumatology Department, Hospital Universitario Araba. Vitoria-Gasteiz, Alava, Spain, 3SERGAS (Servizo Galego de Saude) and IDIS (Instituto de Investigación Sanitaria de Santiago), The NEIRID Group (Neuroendocrine Interactions in Rheumatology and Inflammatory Diseases), Santiago University Clinical Hospital, Santiago de Compostela, Spain, Santiago de Compostela, Spain, 4Department of Epidemiology and Computational Biology, School of Medicine, University of Cantabria, and CIBER Epidemiología y Salud Pública (CIBERESP), IDIVAL, Santander, Spain, Santander, Spain, 5Hospital Universitario La Princesa, IIS-Princesa, Madrid, Spain, 6Cardiovascular Pathophysiology and Genomics Research Unit, School of Physiology, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South Africa, 7School of Medicine, University of Cantabria, Santander, Spain, Santander, Spain

    Background/Purpose: Leptin is an adipokine that plays an important role in the regulation of body weight and also participates in immune homeostasis and inflammatory processes1,2.…
  • Abstract Number: 1528 • 2018 ACR/ARHP Annual Meeting

    Unique Changes in Hemoglobin with Sarilumab Versus Adalimumab Are Independent of Better Disease Control in Patients with Rheumatoid Arthritis (RA)

    Gerd R. Burmester1, Owen Hagino2, Qunming Dong3, Marina Stanislav4, Antonio Gomez-Centeno5, Carlo Selmi6, Tom W.J. Huizinga7, Erin Mangan8, Cem Gabay9 and Mark C. Genovese10, 1Charité – University Medicine Berlin, Free University and Humboldt University Berlin, Berlin, Germany, 2Sanofi Genzyme, Bridgewater, NJ, 3Sanofi, Bridgewater, NJ, 4Scientific Research Institute of Rheumatology, Russian Academy of Medical Sciences, Moscow, Russian Federation, 5Corporació Sanitària Parc Taulí, Barcelona, Spain, 6Rheumatology and Clinical Immunology Unit, Humanitas Research Hospital, Rozzano (MI), Italy, 7Leiden University Medical Center, Leiden, Netherlands, 8Regeneron Pharmaceuticals, Inc., Tarrytown, NY, 9University Hospitals of Geneva, Geneva, Switzerland, 10Stanford University Medical Center, Palo Alto, CA

    Background/Purpose: Anemia (WHO criteria: Hemoglobin [Hb] levels <12.0 g/dL [females] or <13.0 g/dL [males]) is a common finding associated with increased joint inflammation in patients…
  • Abstract Number: 1550 • 2018 ACR/ARHP Annual Meeting

    Improvement of HbA1c in Patients with Rheumatoid Arthritis and Diabetes Type 2 during Treatment with Tocilizumab

    Christof Specker1, Annette Alberding2, Martin Aringer3, Gerd R. Burmester4, Jan-Paul Flacke5, Michael Hofmann6, Peter Kaestner7, Herbert Kellner8, Frank Moosig9, Maren Sieburg10, Hans-Peter Tony11 and Gerhard Fliedner12, 1Rheumatology and Clinical Immunology, Universitätsklinikum Essen, Essen, Germany, 2Internal Rheumatology, Krankenhaus St. Josef, Wuppertal, Germany, 3Medicine III, University Medical Center and Faculty of Medicine TU Dresden, Dresden, Germany, 4Rheumatology and Clinical Immunology, Charité-University Medicine Berlin, Berlin, Germany, 5Rheumatology, Roche Pharma AG, Grenzach-Wyhlen, Germany, 6Rheumatology, Chugai Pharma Europe Ltd., Frankfurt, Germany, 7Rheumatology, Ambulantes Rheumazentrum, Erfurt, Germany, 8Ambulantes Rheumazentrum, Erfurt, Germany, 9Rheumatology Center Schleswig-Holstein Mitte, Neumuenster, Germany, 10Rheumatologische Gemeinschaftspraxis, Magdeburg, Germany, 11Rheumatology/Immunology, Medizinische Klinik II, Universitätsklinik, Würzburg, Germany, 12Rheumatological Practice, Osnabrueck, Germany

    Background/Purpose: Interleukin 6 (IL-6) and C-reactive protein (CRP) are independent risk factors for type 2 diabetes mellitus [1], and IL-6 plays a role in insulin…
  • Abstract Number: 1940 • 2018 ACR/ARHP Annual Meeting

    Reductions in Absolute Neutrophil Count (ANC) with Sarilumab Resulting in Dose Delays or Dose Decreases: Effects on Efficacy and Safety

    Jeffrey R. Curtis1, Gregory St. John2, Michael Pannucci2, Yong Lin3, José A. Maldonado-Cocco4, Tom W.J. Huizinga5, Marina Stanislav6 and Paul Emery7, 1University of Alabama, Birmingham, AL, 2Regeneron Pharmaceuticals, Inc., Tarrytown, NY, 3Sanofi Genzyme, Bridgewater, NJ, 4Universidad de Buenos Aires, Buenos Aires, Argentina, 5Leiden University Medical Center, Leiden, Netherlands, 6Research Rheumatology Institute n. a. V.A. Nassonova, Moscow, Russian Federation, 7University of Leeds and NIHR Leeds Biomedical Research Centre, Leeds, United Kingdom

    Background/Purpose: In sarilumab randomized controlled trials (RCTs), dose delay and/or reduction was recommended for management of patients who developed neutropenia Grade (G) 3 (ANC ≥500…
  • Abstract Number: 1963 • 2018 ACR/ARHP Annual Meeting

    Phenome Wide Association Study of IL6R Variant Identifies Drug Target for Cardiovascular Disease and Inflammation

    Tianxi Cai1,2,3, Yichi Zhang1,3, Yuk-Lam Ho1, Nicholas Link1, Jiehuan Sun1,3, Jie Huang1,4, Tianrun Cai1,2,4, Scott Damrauer5, Yuri Ahuja2, Jacqueline Honerlaw1, Jie Huang1, Lauren Costa1, Petra Schubert1, Chuan Hong3, David Gagnon1,6, Yan Sun7, Michael Gaziano1,2,4, Peter Wilson7,8, Kelly Cho1,2,4, Philip Tsao9, Christopher J. O'Donnell1,2 and Katherine P. Liao1,2,4, 1VA Boston Healthcare System, Boston, MA, 2Harvard Medical School, Boston, MA, 3Harvard T.H. Chan School of Public Health, Boston, MA, 4Brigham and Women's Hospital, Boston, MA, 5Corporal Michael Crescenz VA Medical Center, Perlman School of Medicine, University of Pennsylvania, Philadelphia, PA, 6Boston University School of Public Health, Boston, MA, 7Emory University Schools of Medicine and Public Health, Atlanta, GA, 8Atlanta VA Medical Center, Atlanta, GA, 9VA Palo Alto Health Care System, Department of Medicine, Stanford University School of Medicine, Stanford, CA

    Background/Purpose: Individuals with an interleukin 6 receptor (IL6R) genetic variant not on IL6R blocking therapy have biomarker profiles similar to those treated with IL6R blockers. …
  • Abstract Number: 1985 • 2018 ACR/ARHP Annual Meeting

    IL-1β Inhibits the Expression of Dickkopf-1, an Antagonist of the Wnt-β-Catenin Signaling Pathway: A Possible Role of Inflammasome in Dysregulation of Endochondral Ossification

    Satoshi Yamasaki1, Yusuke Yoshida2, Katsuhiro Oi2, Tatsuomi Kuranobu2, Takaki Nojima2, Hiroaki Ida3 and Eiji Sugiyama4, 1Division of Rheumatology, Kurume University Medical Center, Fukuoka, Japan, 2Department of Clinical Immunology and Rheumatology, Hiroshima University Hospital, Hiroshima, Japan, 3Respiorogy, Neurology and Rheumatology, Kurume University School of Medicine, Kurume, Japan, 4Department of Clinical Immunology and Rheumatology, Department of Clinical Immunology and Rheumatology, Hiroshima University Hospital, Hiroshima, Japan

    Background/Purpose: Aberrant endochondral bone formation in the physis is a unique bone lesion in neonatal-onset multisystem inflammatory disease (NOMID), also called chronic infantile neurologic cutaneous…
  • Abstract Number: 2509 • 2018 ACR/ARHP Annual Meeting

    Long-Term Treatment with Sarilumab Plus Conventional Synthetic Disease-Modifying Anti-Rheumatic Drugs (csDMARDs): Pooled Safety and Efficacy with over 4 Years’ Treatment

    Mark C. Genovese1, Hubert van Hoogstraten2, Gregory St. John3, Qunming Dong2, Juan José Gómez-Reino4, José A. Maldonado-Cocco5, Juan Carlos Salazar6, Tom W.J. Huizinga7 and Gerd R. Burmester8, 1Stanford University Medical Center, Palo Alto, CA, 2Sanofi Genzyme, Bridgewater, NJ, 3Regeneron Pharmaceuticals, Inc., Tarrytown, NY, 4Complejo Hospitalario Universitario de Santiago de Compostela, Santiago, Spain, 5School of Medicine, Buenos Aires University, Buenos Aires, Argentina, 6Riesgo de Fractura S.A - CAYRE, Bogotá, Colombia, 7Leiden University Medical Center, Leiden, Netherlands, 8Charité – University Medicine Berlin, Berlin, Germany

    Background/Purpose: EXTEND (NCT01146652) is an ongoing open-label extension study enrolling patients completing five sarilumab originator studies (MOBILITY [NCT01061736]; TARGET [NCT01709578]; ASCERTAIN [NCT01768572]; ACT11575 [NCT01217814]; ONE…
  • Abstract Number: 2525 • 2018 ACR/ARHP Annual Meeting

    Correlation Analysis between Sirukumab Exposure and Selected Safety Events Following Subcutaneous Administration Using Pooled Phase 3 Data in Rheumatoid Arthritis

    Yan Xu1, Yanli Zhuang1, Chuanpu Hu1, Benjamin Hsu2, Zhenhua Xu1, Amarnath Sharma1 and Honghui Zhou1, 1Global Clinical Pharmacology, Janssen Research & Development, LLC, Spring House, PA, 2Immunology Clinical Development, Janssen Research & Development, LLC, Spring House, PA

    Background/Purpose: To characterize the exposure-response (ER) relationship between systemic exposure to sirukumab (an anti- interleukin-6 [IL-6] human monoclonal antibody) and the occurrence of selected safety…
  • Abstract Number: 317 • 2018 ACR/ARHP Annual Meeting

    Imaging Biomarker Based Patient Stratification: Initial Data and Validation in Four Most Common Knee Arthritic Diseases

    Olga Kubassova1, Mikael Boesen2, Adam Taylor3, Robert Riis4, Lars Hornum5, Henning Bliddal2, Christine Ballegaard6 and Else Marie Bartels4, 1R&D, IAG, Image Analysis Group, London, United Kingdom, 2Department of Rheumatology, The Parker Institute, Copenhagen University Hospital at Frederiksberg, Frederiksberg, Denmark, 3IAG, Image Analysis Group, London, United Kingdom, 4The Parker Institute, Copenhagen University Hospital at Frederiksberg, Frederiksberg, Denmark, 5Novo Nordisk A/S, Måløv, Denmark, 6The Parker Institute, Copenhagen University Hospital, Bispebjerg and Frederiksberg, Copenhagen F, Denmark

    Background/Purpose: Biomarker science has advanced to aid in distinguishing between different forms of arthritis: inflammatory arthritides such as rheumatoid arthritis (RA) and psoriatic arthritis (PsA)…
  • « Previous Page
  • 1
  • 2
  • 3
  • 4
  • …
  • 9
  • Next Page »
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology